ReviewBlood cancer journal2017
Current applications of multiparameter flow cytometry in plasma cell disorders.
Review in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06109233 (A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.International journal of molecular sciences · 2026Review
- Article
- Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS.Blood advances · 2025Article
- Comparative Diagnostic Performance of Flow Cytometry, Aspiration, and Biopsy with Immunohistochemistry in Plasma Cell Neoplasms.International journal of hematology-oncology and stem cell research · 2025Article
- Applications of Multiparameter Flow Cytometry in the Diagnosis, Prognosis, and Monitoring of Multiple Myeloma Patients.Diseases (Basel, Switzerland) · 2025Review
- Circulating plasma cells: from basic mechanisms to clinical applications.Frontiers in immunology · 2025Review
- Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.European journal of haematology · 2025Article
- CAR T-cell therapy to treat multiple myeloma: current state and future directions.Cancer metastasis reviews · 2024Review
- Article
- Immunophenotypic Profile of Multiple Myeloma: A Tertiary Care Centre Experience.Journal of laboratory physicians · 2023Article
- Circulating biosignatures in multiple myeloma and their role in multidrug resistance.Molecular cancer · 2023Review
- More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.International journal of molecular sciences · 2022Article
- Review
- CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.Journal of clinical medicine · 2022Article
- Junctional adhesion molecule C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans.Blood advances · 2022Article
- Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.Journal of clinical medicine · 2022Review
- Article
- Review
- Flow cytometric monitoring of the bacterial phenotypic diversity in aquatic ecosystems.Journal of microbiology (Seoul, Korea) · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic work-up because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenström macroglobulinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.